Abstract

A VALIDATED RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF PREGABALIN AND ETORICOXIB IN PHARMACEUTICAL DOSAGE FORM

M. Guruvareddy* and K. Kamalamma

ABSTRACT

For the simultaneous estimation of Pregabalin and Etoricoxib in API and pharmaceutical dosage form, a simple, precise, accurate, and durable reverse phase RP-HPLC method has been devised and validated. This approach uses a simple isocratic mobile phase of acetonitrile: 0.01N Sodium dihydrogen phosphate (60:40), Discovery C18 (150x 4.6mm, 5μm) column, and WATERS 2695 HPLC system for chromatographic separation and PDA detection. Pregabalin and Etoricoxib had average retention durations of 2.227 and 2.972 minutes, respectively. The % assay for Pregabalin and Etoricoxib was determined to be 99.50% and 100.60%, respectively, indicating that the method is suitable for routine analysis. The linearity of Pregabalin and Etoricoxib was discovered to be linear, with an R2 of 0.999 for all medications, indicating that the approach can yield good sensitivity. The precision acceptance criteria are that the % RSD should not exceed 2.0%, and the method displays precision of 1.6 and 1.4 for Pregabalin and Etoricoxib, respectively, indicating that the method is precise.

Keywords: Method development, Pregabalin. Etoricoxib, Method Validation.